Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (301)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02458508 | Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy(GLIOMELA) | completed | — | 65 | University of PisaOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02725684 | Using Genomic Analysis to Guide Individual Treatment in Glioblastoma | completed | — | 36 | Rockefeller UniversityOTHER | 1 | Oct 25, 2017 |
| clinicaltrials |
| NCT01956734 | Virus DNX2401 and Temozolomide in Recurrent Glioblastoma(D24GBM) | completed | Phase 1 | 31 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT02006563 | Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors | completed | — | 22 | University of MiamiOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT03310372 | Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme(TEMOFRAC) | completed | Phase 2 | 46 | Central Hospital, Nancy, FranceOTHER | 0 | Oct 17, 2017 | clinicaltrials |
| NCT01867593 | MET-PET for Newly Diagnosed Glioblastoma | completed | Early Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Oct 13, 2017 | clinicaltrials |
| NCT01310868 | Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | completed | Phase 2 | 59 | University College, LondonOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT00943826 | A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma | completed | Phase 3 | 921 | Hoffmann-La RocheINDUSTRY | 24 | Sep 25, 2017 | clinicaltrials |
| NCT02490930 | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | completed | Early Phase 1 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 13, 2017 | clinicaltrials |
| NCT00187486 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | completed | Phase 2 | 66 | University of California, San FranciscoOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02029573 | Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma(ART) | completed | Phase 2 | 36 | King Fahad Medical CityOTHER_GOV | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00540722 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01975116 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | completed | Phase 1 | 18 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 7, 2017 | clinicaltrials |
| NCT02887417 | Glioblastoma Platelet Activation Study(GPAS) | completed | — | 21 | University Medicine GreifswaldOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 59 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | completed | Phase 2 | 45 | University of WashingtonOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00686725 | Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) | completed | Phase 4 | 99 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 14, 2017 | clinicaltrials |
| NCT01149109 | Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients(CeTeG) | completed | Phase 3 | 141 | University Hospital, BonnOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | completed | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00684567 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | completed | Phase 2 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00345163 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)(BRAIN) | completed | Phase 2 | 167 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00660543 | MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy | completed | N/A | 14 | OHSU Knight Cancer InstituteOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT00335075 | Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) | completed | Phase 3 | 151 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT01393912 | PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma | completed | Phase 1 | 55 | St. Jude Children's Research HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT02550249 | Neoadjuvant Nivolumab in Glioblastoma(Neo-nivo) | completed | Phase 2 | 29 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00916409 | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | completed | Phase 3 | 700 | NovoCure Ltd.INDUSTRY | 12 | Apr 10, 2017 | clinicaltrials |
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01268566 | A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 62 | MedImmune LLCINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01929720 | Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors(FOCUS) | completed | N/A | 33 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00883298 | Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 30 | Center for Neurosciences, TucsonOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00792012 | A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma | completed | Phase 1 | 37 | University of Colorado, DenverOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT01280552 | A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) | completed | Phase 2 | 124 | Precision Life Sciences GroupINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00459381 | Pazopanib in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01738646 | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | completed | Phase 2 | 48 | Duke UniversityOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01836536 | Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients(AVA-CELL) | completed | N/A | 30 | Center Eugene MarquisOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT01250470 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT01238237 | Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA | completed | Phase 1 | 15 | Northwell HealthOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT00813943 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status(CORE) | completed | Phase 2 | 265 | EMD SeronoINDUSTRY | 2 | Jan 30, 2017 | clinicaltrials |
| NCT00085540 | FR901228 in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2017 | clinicaltrials |
| NCT00777153 | Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma(REGAL) | completed | Phase 3 | 423 | AstraZenecaINDUSTRY | 10 | Dec 28, 2016 | clinicaltrials |
| NCT01308684 | A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma | completed | Phase 1 | 22 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01547546 | A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma | completed | Phase 1 | 29 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01443676 | Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma(ARTE) | completed | Phase 2 | 75 | University of ZurichOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT02104882 | INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study | completed | Phase 1 / Phase 2 | 12 | Universitätsmedizin MannheimOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00088400 | Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors | completed | Phase 3 | 30 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 22, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2017source: clinicaltrials